Blog

  • Immune Cells Ignore Retinal Damage While Microglia Step In

    Immune Cells Ignore Retinal Damage While Microglia Step In

    Summary: Unlike most tissues, the retina doesn’t summon neutrophils—the body’s typical first responders—when injured. Instead, microglia, the brain’s resident immune cells, handle photoreceptor damage without calling for backup.

    Using adaptive optics imaging, researchers observed this unique immune behavior in live mouse retinas. The findings suggest a protective “cloaking” mechanism that prevents excessive inflammation and may inform future treatments for vision loss.

    Key Facts:

    • Retina-Specific Response: Neutrophils do not assist in photoreceptor repair despite being nearby.
    • Microglia Activation: Only brain-resident immune cells respond to retinal injury.
    • Inflammation Shield: The retina may suppress immune cell recruitment to prevent further damage.

    Source: University of Rochester

    During most eye infections or injuries, neutrophils, immune cells found in the blood, are usually the first line of defense.

    However, researchers at the Flaum Eye Institute and Del Monte Institute for Neuroscience at the University of Rochester have discovered that the retina responds differently than many other tissues in the body.

    When photoreceptor cells in the retina are damaged, microglia, or the brain’s immune cells, respond, and the neutrophils are not recruited to help despite passing through nearby blood vessels.

    Photoreceptor cells are unique to the retina. Credit: Neuroscience News

    “This finding has high implications for what happens for millions of Americans who suffer vision loss through loss of photoreceptors,” said Jesse Schallek, PhD, associate professor of Ophthalmology and senior author of a study out today in eLife.

    “This association between two key immune cell populations is essential knowledge as we build new therapies that must understand the nuance of immune cell interactions.”

    Using adaptive optics imaging, a camera technology developed by the University of Rochester that allows the imaging of single neurons and immune cells inside the living eye, researchers studied the retinas of mice with photoreceptor damage.

    They found that while both neutrophil and microglia cells are present in the retina, only microglia cells respond to photoreceptor injury, and they do not call upon neutrophils to help repair the photoreceptor damage.

    Researchers believe this suggests a type of cloaking occurs during retinal injury to protect the retina from a rush of immune cells that could do more harm than good.

    “What is remarkable here is that the passing neutrophils are so close to the reactive microglia, and yet they do not signal to them to assist in damage recovery,” said Schallek.

    “This is notably different than what is seen in other areas of the body where neutrophils are the first to respond to local damage and mount an early and robust response.”

    Photoreceptor cells are unique to the retina. They process light into electrical and chemical signals, communicate that information to our brain, which allows us to see.

    There are many diseases that damage and kill photoreceptor cells, including age-related macular degeneration, retinitis pigmentosa, and cone-rod dystrophy, and currently, there is no cure.

    This research now shows it is possible to visualize the dynamics of single cells as they communicate with each other, as the retina responds to damage.

    First author Derek Power, a laboratory technician in the Schallek lab, led the study. Other authors include Justin Elstrott, PhD, of Genentech Inc.

    Funding: The research was supported by the National Eye Institute, Research to Prevent Blindness, Dana Foundation, and a Collaborative Research Grant from Genentech, Inc.

    About this visual neuroscience research news

    Author: Kelsie Smith Hayduk
    Source: University of Rochester
    Contact: Kelsie Smith Hayduk – University of Rochester
    Image: The image is credited to Neuroscience News

    Original Research: Open access.
    “Photoreceptor loss does not recruit neutrophils despite strong microglial activation” by Derek Power et al. eLife

    Abstract

    Photoreceptor loss does not recruit neutrophils despite strong microglial activation

    In response to central nervous system (CNS) injury, tissue-resident immune cells such as microglia and circulating systemic neutrophils are often first responders.

    The degree to which these cells interact in response to CNS damage is poorly understood, and even less so, in the neural retina, which poses a challenge for high-resolution imaging in vivo.

    In this study, we deploy fluorescence adaptive optics scanning light ophthalmoscopy (AOSLO) to study microglia and neutrophils in mice.

    We simultaneously track immune cell dynamics using label-free phase-contrast AOSLO at micron-level resolution. Retinal lesions were induced with 488 nm light focused onto photoreceptor (PR) outer segments.

    These lesions focally ablated PRs, with minimal collateral damage to cells above and below the plane of focus.

    We used in vivo AOSLO, and optical coherence tomography (OCT) imaging to reveal the natural history of the microglial and neutrophil response from minutes to months after injury.

    While microglia showed dynamic and progressive immune response with cells migrating into the injury locus within 1 day after injury, neutrophils were not recruited despite close proximity to vessels carrying neutrophils only microns away. Post-mortem confocal microscopy confirmed in vivo findings.

    This work illustrates that microglial activation does not recruit neutrophils in response to acute, focal loss of PRs, a condition encountered in many retinal diseases.

    Continue Reading

  • Tour de France Daily | Stage 18 | Huge team effort keeps Ben Healy in top ten on GC

    Tour de France Daily | Stage 18 | Huge team effort keeps Ben Healy in top ten on GC

    Harry Sweeny joined our team in 2024 and quickly became a key rider for us in the classics and grand tours. This is the Australian’s fifth season as a pro.

    Harry is still discovering his limits as a racer. As a U23, he won Il Piccolo Lombardia and has since ridden the Tour de France, where, as a rookie, he finished third on a stage and rode onto the Champs-Élysées in the break, as jets trailed bleu, blanc, et rouge streaks into the sky overhead. He has raced Paris-Roubaix in the wet and Liège-Bastogne-Liège alongside his friend, the former winner and cycling legend, Philippe Gilbert. Last year, he finished seventh on GC at the Tour of Luxembourg after riding hard for his teammates all season. Harry believes that his best is yet to come.

    He came to cycling late. As a kid growing up in Brisbane, where his family moved when he was a child, he played soccer and rugby and did gymnastics and swam. He took up triathlon as a schoolboy, but focused on cycling when he was a junior and was recovering from a running injury. He started out racing local crits. His athleticism soon shone and he was picked to race the world championships in Richmond, Virginia for the Australian national team.

    He moved to Europe to race, first for a small junior team in Belgium, and then for two years with the Australian Institute of Sport squad, which was then based in Italy, before moving back to Belgium for his final year as an U23. Those years opened up new worlds for Harry.

    EF Education-EasyPost’s open-minded international character is a big draw for him. On the teams he has raced for in the past, he has often been one of the few foreigners. Our team is made up of riders and staff from dozens of nationalities. Most of them know what it is like to build a life far from home and can help with all of the little difficulties that come with that. Our multicultural make up helps us to expand our outlook and think beyond traditional ways of doing things too.

    Harry is a lot more than a bike racer. He is a keen cook and he loves to go camping and hiking with his girlfriend, an environmental scientist, near their adopted home in Andorra. In the winter, he loves to ski. And he is a YouTuber.

    This summer, Harry will return to the Tour de France in EF Education-EasyPost pink. We know that we can always count on him to be where we need him to be when it counts – and to bring a laugh to the bus.

    Continue Reading

  • Intel Reports Second-Quarter 2025 Financial Results :: Intel Corporation (INTC)

    Intel Reports Second-Quarter 2025 Financial Results :: Intel Corporation (INTC)








    News Summary

    • Second-quarter revenue was $12.9 billion, flat year-over-year (YoY).

    • Second-quarter earnings (loss) per share (EPS) attributable to Intel was $(0.67); non-GAAP EPS attributable to Intel was $(0.10).

    • $(0.45) impact to GAAP EPS attributable to Intel from $1.9 billion of restructuring charges; $(0.23) and $(0.20) impact to GAAP and non-GAAP EPS attributable to Intel, respectively, from $800 million of impairment charges and $200 million in one-time period costs.

    • Forecasting third-quarter 2025 revenue of $12.6 billion to $13.6 billion; expecting third-quarter EPS attributable to Intel of $(0.24) and non-GAAP EPS attributable to Intel of $0.00.

    • Taking actions to drive improved execution and efficiency; continue to target $17 billion of non-GAAP1 operating expenses in 2025 and $16 billion in 2026; $18 billion in gross capital expenditures for 2025.

    SANTA CLARA, Calif.–(BUSINESS WIRE)–
    Intel Corporation today reported second-quarter 2025 financial results.

    “Our operating performance demonstrates the initial progress we are making to improve our execution and drive greater efficiency,” said Lip-Bu Tan, Intel CEO. “We are laser-focused on strengthening our core product portfolio and our AI roadmap to better serve customers. We are also taking the actions needed to build a more financially disciplined foundry. It’s going to take time, but we see clear opportunities to enhance our competitive position, improve our profitability and create long-term shareholder value.”

    “Our results reflect solid demand across our business and good execution on our priorities,” said David Zinsner, Intel CFO. “The changes we are making to reduce our operating costs, improve our capital efficiency and monetize non-core assets are having a positive impact as we work to strengthen our balance sheet and position the business for the future.”

    Progress on Driving Greater Efficiency and Execution

    Intel continues to make progress to simplify its business, improve efficiency and enhance execution. These efforts are focused on reducing expenses, strengthening the balance sheet, optimizing the global footprint and concentrating resources on the most critical growth areas.

    • On track to achieve $17 billion non-GAAP operating expense1 target for 2025: Intel has completed the majority of the planned headcount actions it announced last quarter to reduce its core workforce by approximately 15%. These changes are designed to create a faster-moving, flatter and more agile organization. As a result of these actions, the company recognized $1.9 billion in restructuring charges in the second quarter of 2025, which were excluded from its non-GAAP results. These charges impacted GAAP EPS by $(0.45) per share. Intel plans to end the year with a core workforce of about 75,000 employees as a result of workforce reductions and attrition.

    • Improving capital efficiency; driving to gross capital expenditures2 of $18 billion for 2025: Intel is taking action to optimize its manufacturing footprint and drive greater returns on invested capital. As part of this effort, Intel will no longer move forward with planned projects in Germany and Poland. The company also intends to consolidate its assembly and test operations in Costa Rica into its larger sites in Vietnam and Malaysia. In addition, Intel will further slow the pace of construction in Ohio to ensure spending is aligned with market demand.

    Intel also recognized approximately $800 million of non-cash impairment and accelerated depreciation charges related to excess tools with no identified re-use and approximately $200 million of one-time period costs in the second quarter of 2025. These charges reduced both GAAP and non-GAAP gross margin by approximately 800 basis points and GAAP and non-GAAP EPS by approximately $(0.23) and $(0.20) cents per share, respectively.

    These restructuring charges and impairments were not incorporated into the guidance Intel provided for the second quarter of 2025.

    1

    		  

    Non-GAAP operating expense refers to non-GAAP R&D and marketing, general and administrative (MG&A). See below for more information on and reconciliations of Intel’s non-GAAP financial measures.

    2

    		  

    Gross capital expenditures refers to GAAP additions to property, plant and equipment.

    Q2 2025 Financial Results

     

    GAAP

     

    Non-GAAP

     

    Q2 2025

    Q2 2024

    vs. Q2 2024

     

    Q2 2025

    Q2 2024

    vs. Q2 2024

    Revenue ($B)

    $12.9

    $12.8

    flat

     

     

     

     

    Gross margin

    27.5%

    35.4%

    down 7.9 ppts

     

    29.7%

    38.7%

    down 9 ppts

    R&D and MG&A ($B)

    $4.8

    $5.6

    down 13%

     

    $4.3

    $4.9

    down 13%

    Operating margin (loss)

    (24.7)%

    (15.3)%

    down 9.4 ppts

     

    (3.9)%

    0.2%

    down 4.1 ppts

    Tax rate

    (9.2)%

    17.5%

    down 26.7 ppts

     

    12.0%

    13.0%

    down 1 ppt

    Net income (loss) attributable to Intel ($B)

    $(2.9)

    $(1.6)

    down 81%

     

    $(0.4)

    $0.1

    *n/m

    Earnings (loss) per share attributable to Intel—diluted

    $(0.67)

    $(0.38)

    down 76%

     

    $(0.10)

    $0.02

    *n/m

    In the second quarter, the company generated $2.1 billion in cash from operations.

    Full reconciliations between GAAP and non-GAAP measures are provided below.

    *Not meaningful

    Business Unit Summary

    In the first quarter of 2025, the company made an organizational change to integrate the Network and Edge Group (NEX) into CCG and DCAI and modified Intel’s segment reporting to align to this and certain other business reorganizations. All prior-period segment data has been retrospectively adjusted to reflect the way Intel’s chief operating decision maker internally receives information and manages and monitors the company’s operating segment performance. There are no changes to Intel’s consolidated financial statements for any prior periods.

    Business Unit Revenue and Trends

     

    Q2 20253

     

    vs. Q2 2024

    Intel Products:

     

     

     

     

     

    Client Computing Group (CCG)

     

    $7.9 billion

     

    down

    3%

    Data Center and AI (DCAI)

     

    $3.9 billion

     

    up

    4%

    Total Intel Products revenue

     

    $11.8 billion

     

    down

    1%

    Intel Foundry

     

    $4.4 billion

     

    up

    3%

    All Other

     

    $1.1 billion

     

    up

    20%

    Intersegment Eliminations

     

    $(4.4) billion

     

     

     

    Total net revenue

     

    $12.9 billion

     

    flat

     

    3

    		  

    Numbers are presented as actual and rounded; as a result, totals may not sum.

    Business Highlights

    • Intel launched three new additions to its Intel® Xeon® 6 series of central processing units (CPUs), delivering customizable CPU core frequencies to boost graphics processing unit (GPU) performance across demanding AI workloads. One of these, the Intel® Xeon® 6776P processor, currently serves as the host CPU for NVIDIA DGX B300, the company’s latest generation of AI-accelerated systems.

    • The first Panther Lake processor SKU remains on track to begin shipping later this year, with additional SKUs coming in the first half of 2026.

    • Intel 18A reached a key milestone with the start of production wafers in Arizona.

    • Intel made key leadership appointments, including Greg Ernst as chief revenue officer and Srinivasan Iyengar, Jean-Didier Allegrucci and Shailendra Desai in key engineering leadership roles.

    • In line with Intel’s commitment to strengthen its balance sheet and monetize non-core assets, the company sold, via a secondary offering, 57.5 million of net Class A shares of Mobileye in July 2025, adding approximately $922 million to the balance sheet. Intel remains the majority shareholder in Mobileye and continues to have strong conviction in its long-term growth opportunity.

    Business Outlook

    Intel’s guidance for the third quarter of 2025 includes both GAAP and non-GAAP estimates as follows:

    Q3 2025

     

    GAAP

     

    Non-GAAP

    Revenue

     

    $12.6-13.6 billion

     

     

    Gross margin

     

    34.1%

     

    36.0%

    Tax Rate

     

    (23)%

     

    12%

    Earnings (Loss) Per Share Attributable to Intel—Diluted

     

    $(0.24)

     

    $0.00

    Reconciliations between GAAP and non-GAAP financial measures are included below. Actual results may differ materially from Intel’s business outlook as a result of, among other things, the factors described under “Forward-Looking Statements” below. The gross margin and EPS outlooks are based on the midpoint of the revenue range.

    Earnings Webcast

    Intel will hold a public webcast at 2 p.m. PDT today to discuss the results for its second quarter of 2025. The live public webcast can be accessed on Intel’s Investor Relations website at www.intc.com. The corresponding earnings presentation and webcast replay will also be available on the site.

    Forward-Looking Statements

    This release contains forward-looking statements that involve a number of risks and uncertainties. Words such as “accelerate”, “achieve”, “aim”, “ambitions”, “anticipate”, “believe”, “committed”, “continue”, “could”, “designed”, “estimate”, “expect”, “forecast”, “future”, “goals”, “grow”, “guidance”, “intend”, “likely”, “may”, “might”, “milestones”, “next generation”, “objective”, “on track”, “opportunity”, “outlook”, “pending”, “plan”, “position”, “possible”, “potential”, “predict”, “progress”, “ramp”, “roadmap”, “seek”, “should”, “strive”, “targets”, “to be”, “upcoming”, “will”, “would”, and variations of such words and similar expressions are intended to identify such forward-looking statements, which may include statements regarding:

    • our business plans and strategy and anticipated benefits therefrom, including with respect to our IDM strategy, Smart Capital strategy, partnerships with Apollo and Brookfield, internal foundry model, updated reporting structure, and AI strategy;

    • projections of our future financial performance, including future revenue, gross profits, capital expenditures, and cash flows;

    • projected costs and yield trends;

    • future cash requirements, the availability, uses, sufficiency, and cost of capital resources, and sources of funding, including for future capital and R&D investments and for returns to stockholders, such as stock repurchases and dividends, and credit ratings expectations;

    • future products, services, and technologies, and the expected goals, timeline, ramps, progress, availability, production, regulation, and benefits of such products, services, and technologies, including future process nodes and packaging technology, product roadmaps, schedules, future product architectures, expectations regarding process performance, per-watt parity, and metrics, and expectations regarding product and process leadership;

    • investment plans and impacts of investment plans, including in the US and abroad;

    • internal and external manufacturing plans, including future internal manufacturing volumes, manufacturing expansion plans and the financing therefor, and external foundry usage;

    • future production capacity and product supply;

    • supply expectations, including regarding constraints, limitations, pricing, and industry shortages;

    • plans and goals related to Intel’s foundry business, including with respect to anticipated customers, future manufacturing capacity and service, technology, and IP offerings;

    • expected timing and impact of acquisitions, divestitures, and other significant transactions, including the agreed-upon sale of a controlling interest of Altera;

    • expected completion and impacts of restructuring activities and cost-saving or efficiency initiatives;

    • future social and environmental performance goals, measures, strategies, and results;

    • our anticipated growth, future market share, customer demand, and trends in our businesses and operations;

    • projected growth and trends in markets relevant to our businesses;

    • anticipated trends and impacts related to industry component, substrate, and foundry capacity utilization, shortages, and constraints;

    • expectations regarding government incentives, policies, and priorities;

    • future technology trends and developments, such as AI;

    • future macro environmental and economic conditions;

    • geopolitical tensions and conflicts, including with respect to international trade policies in areas such as tariffs and export controls, and their potential impact on our business;

    • tax- and accounting-related expectations;

    • expectations regarding our relationships with certain sanctioned parties; and

    • other characterizations of future events or circumstances.

    Such statements involve many risks and uncertainties that could cause our actual results to differ materially from those expressed or implied, including those associated with:

    • the high level of competition and rapid technological change in our industry;

    • the significant long-term and inherently risky investments we are making in R&D and manufacturing facilities that may not realize a favorable return;

    • the complexities and uncertainties in developing and implementing new semiconductor products and manufacturing process technologies;

    • our ability to time and scale our capital investments appropriately and successfully secure favorable alternative financing arrangements and government grants;

    • implementing new business strategies and investing in new businesses and technologies;

    • changes in demand for our products;

    • macroeconomic conditions and geopolitical tensions and conflicts, including geopolitical and trade tensions between the US and China, the impacts of Russia’s war on Ukraine, tensions and conflict affecting Israel and the Middle East, and rising tensions between mainland China and Taiwan;

    • the evolving market for products with AI capabilities;

    • our complex global supply chain supporting our manufacturing facilities and incorporating external foundries, including from disruptions, delays, trade tensions and conflicts, or shortages;

    • recently elevated geopolitical tensions, volatility and uncertainty with respect to international trade policies, including tariffs and export controls, impacting our business, the markets in which we compete and the world economy;

    • product defects, errata and other product issues, particularly as we develop next-generation products and implement next-generation manufacturing process technologies;

    • potential security vulnerabilities in our products;

    • increasing and evolving cybersecurity threats and privacy risks;

    • IP risks including related litigation and regulatory proceedings;

    • the need to attract, retain, and motivate key talent;

    • strategic transactions and investments;

    • sales-related risks, including customer concentration and the use of distributors and other third parties;

    • our significantly reduced return of capital in recent years;

    • our debt obligations and our ability to access sources of capital;

    • complex and evolving laws and regulations across many jurisdictions;

    • fluctuations in currency exchange rates;

    • changes in our effective tax rate;

    • catastrophic events;

    • environmental, health, safety, and product regulations;

    • our initiatives and new legal requirements with respect to corporate responsibility matters; and

    • other risks and uncertainties described in this release, our 2024 Form 10-K, our Q1 2025 Form 10-Q, our Q2 2025 Form 10-Q, and our other filings with the SEC.

    Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Readers are urged to carefully review and consider the various disclosures made in this release and in other documents we file from time to time with the SEC that disclose risks and uncertainties that may affect our business.

    Unless specifically indicated otherwise, the forward-looking statements in this release do not reflect the potential impact of any divestitures, mergers, acquisitions, or other business combinations that have not been completed as of the date of this filing. In addition, the forward-looking statements in this release are based on management’s expectations as of the date of this release, unless an earlier date is specified, including expectations based on third-party information and projections that management believes to be reputable. We do not undertake, and expressly disclaim any duty, to update such statements, whether as a result of new information, new developments, or otherwise, except to the extent that disclosure may be required by law.

    About Intel

    Intel (Nasdaq: INTC) is an industry leader, creating world-changing technology that enables global progress and enriches lives. Inspired by Moore’s Law, we continuously work to advance the design and manufacturing of semiconductors to help address our customers’ greatest challenges. By embedding intelligence in the cloud, network, edge and every kind of computing device, we unleash the potential of data to transform business and society for the better. To learn more about Intel’s innovations, go to newsroom.intel.com and intel.com.

    © Intel Corporation. Intel, the Intel logo, and other Intel marks are trademarks of Intel Corporation or its subsidiaries. Other names and brands may be claimed as the property of others.

    Intel Corporation

    Consolidated Condensed Statements of Operations and Other Information
     

     

     

    Three Months Ended

    (In Millions, Except Per Share Amounts; Unaudited)

     

    Jun 28, 2025

     

    Jun 29, 2024

    Net revenue

     

    $

    12,859

     

     

    $

    12,833

     

    Cost of sales

     

     

    9,317

     

     

     

    8,286

     

    Gross profit

     

     

    3,542

     

     

     

    4,547

     

    Research and development

     

     

    3,684

     

     

     

    4,239

     

    Marketing, general, and administrative

     

     

    1,144

     

     

     

    1,329

     

    Restructuring and other charges

     

     

    1,890

     

     

     

    943

     

    Operating expenses

     

     

    6,718

     

     

     

    6,511

     

    Operating income (loss)

     

     

    (3,176

    )

     

     

    (1,964

    )

    Gains (losses) on equity investments, net

     

     

    502

     

     

     

    (120

    )

    Interest and other, net

     

     

    (95

    )

     

     

    80

     

    Income (loss) before taxes

     

     

    (2,769

    )

     

     

    (2,004

    )

    Provision for (benefit from) taxes

     

     

    255

     

     

     

    (350

    )

    Net income (loss)

     

     

    (3,024

    )

     

     

    (1,654

    )

    Less: net income (loss) attributable to non-controlling interests

     

     

    (106

    )

     

     

    (44

    )

    Net income (loss) attributable to Intel

     

    $

    (2,918

    )

     

    $

    (1,610

    )

    Earnings (loss) per share attributable to Intel—basic

     

    $

    (0.67

    )

     

    $

    (0.38

    )

    Earnings (loss) per share attributable to Intel—diluted

     

    $

    (0.67

    )

     

    $

    (0.38

    )

     

     

     

     

     

    Weighted average shares of common stock outstanding:

     

     

     

     

    Basic

     

     

    4,369

     

     

     

    4,267

     

    Diluted

     

     

    4,369

     

     

     

    4,267

     

    Other information:

     

     

     

     

     

     

    (In Thousands; Unaudited)

     

    Jun 28, 2025

     

    Mar 29, 2025

     

    Jun 29, 2024

    Employees

     

     

     

     

     

     

    Intel

     

    96.4

     

    97.6

     

    116.5

    Mobileye and other subsidiaries

     

    5.0

     

    5.0

     

    5.3

    NAND1

     

    —

     

    —

     

    3.5

    Total Intel

     

    101.4

     

    102.6

     

    125.3

    1

    Employees of the NAND memory business, which we divested to SK hynix upon the first closing on Dec. 29, 2021, and fully deconsolidated in Q1 2022. Employees are excluded from Intel’s total employee count following the completion of the second closing of the divestiture on March 27, 2025.

    Intel Corporation

    Consolidated Condensed Balance Sheets

    (In Millions, Except Par Value; Unaudited)

     

    Jun 28, 2025

     

    Dec 28, 2024

    Assets

     

     

     

     

    Current assets:

     

     

     

     

    Cash and cash equivalents

     

    $

    9,643

     

    $

    8,249

     

    Short-term investments

     

     

    11,563

     

     

    13,813

     

    Accounts receivable, net

     

     

    2,360

     

     

    3,478

     

    Inventories

     

     

     

     

    Raw materials

     

     

    1,194

     

     

    1,344

     

    Work in process

     

     

    6,484

     

     

    7,432

     

    Finished goods

     

     

    3,699

     

     

    3,422

     

     

     

     

    11,377

     

     

    12,198

     

    Other current assets

     

     

    8,432

     

     

    9,586

     

    Total current assets

     

     

    43,375

     

     

    47,324

     

     

     

     

     

     

    Property, plant, and equipment, net

     

     

    109,510

     

     

    107,919

     

    Equity investments

     

     

    5,383

     

     

    5,383

     

    Goodwill

     

     

    23,912

     

     

    24,693

     

    Identified intangible assets, net

     

     

    3,057

     

     

    3,691

     

    Other long-term assets

     

     

    7,283

     

     

    7,475

     

    Total assets

     

    $

    192,520

     

    $

    196,485

     

     

     

     

     

     

    Liabilities and stockholders’ equity

     

     

     

     

    Current liabilities:

     

     

     

     

    Accounts payable

     

     

    10,666

     

     

    12,556

     

    Accrued compensation and benefits

     

     

    4,249

     

     

    3,343

     

    Short-term debt

     

     

    6,731

     

     

    3,729

     

    Income taxes payable

     

     

    887

     

     

    1,756

     

    Other accrued liabilities

     

     

    12,433

     

     

    14,282

     

    Total current liabilities

     

     

    34,966

     

     

    35,666

     

     

     

     

     

     

    Debt

     

     

    44,026

     

     

    46,282

     

    Other long-term liabilities

     

     

    7,777

     

     

    9,505

     

    Stockholders’ equity:

     

     

     

     

    Common stock and capital in excess of par value, 4,377 issued and outstanding (4,330 issued and outstanding as of December 28, 2024)

     

     

    52,334

     

     

    50,949

     

    Accumulated other comprehensive income (loss)

     

     

    65

     

     

    (711

    )

    Retained earnings

     

     

    45,484

     

     

    49,032

     

    Total Intel stockholders’ equity

     

     

    97,883

     

     

    99,270

     

    Non-controlling interests

     

     

    7,868

     

     

    5,762

     

    Total stockholders’ equity

     

     

    105,751

     

     

    105,032

     

    Total liabilities and stockholders’ equity

     

    $

    192,520

     

    $

    196,485

     

    Intel Corporation

    Consolidated Condensed Statements of Cash Flows

     

     

    Six Months Ended

    (In Millions; Unaudited)

     

    Jun 28, 2025

     

    Jun 29, 2024

     

     

     

     

     

    Cash and cash equivalents, beginning of period

     

    $

    8,249

     

     

    $

    7,079

     

    Cash flows provided by (used for) operating activities:

     

     

     

     

    Net income (loss)

     

     

    (3,911

    )

     

     

    (2,091

    )

    Adjustments to reconcile net income (loss) to net cash provided by operating activities:

     

     

     

     

    Depreciation

     

     

    5,213

     

     

     

    4,403

     

    Share-based compensation

     

     

    1,348

     

     

     

    1,959

     

    Restructuring and other charges

     

     

    382

     

     

     

    219

     

    Amortization of intangibles

     

     

    474

     

     

     

    717

     

    (Gains) losses on equity investments, net

     

     

    (390

    )

     

     

    (84

    )

    Deferred taxes

     

     

    106

     

     

     

    (1,339

    )

    Impairments and net (gain) loss on retirement of property, plant, and equipment

     

     

    482

     

     

     

    126

     

    Changes in assets and liabilities:

     

     

     

     

    Accounts receivable

     

     

    1,004

     

     

     

    272

     

    Inventories

     

     

    99

     

     

     

    (116

    )

    Accounts payable

     

     

    114

     

     

     

    181

     

    Accrued compensation and benefits

     

     

    1,022

     

     

     

    (1,015

    )

    Income taxes

     

     

    (1,338

    )

     

     

    (835

    )

    Other assets and liabilities

     

     

    (1,742

    )

     

     

    (1,328

    )

    Total adjustments

     

     

    6,774

     

     

     

    3,160

     

    Net cash provided by (used for) operating activities

     

     

    2,863

     

     

     

    1,069

     

    Cash flows provided by (used for) investing activities:

     

     

     

     

    Additions to property, plant, and equipment

     

     

    (8,733

    )

     

     

    (11,652

    )

    Proceeds from capital-related government incentives

     

     

    964

     

     

     

    699

     

    Purchases of short-term investments

     

     

    (5,730

    )

     

     

    (17,634

    )

    Maturities and sales of short-term investments

     

     

    8,575

     

     

     

    17,214

     

    Proceeds from divestitures

     

     

    1,935

     

     

     

    —

     

    Other investing

     

     

    984

     

     

     

    (355

    )

    Net cash provided by (used for) investing activities

     

     

    (2,005

    )

     

     

    (11,728

    )

    Cash flows provided by (used for) financing activities:

     

     

     

     

    Issuance of commercial paper, net of issuance costs

     

     

    3,493

     

     

     

    5,804

     

    Repayment of commercial paper

     

     

    (1,496

    )

     

     

    (2,609

    )

    Partner contributions

     

     

    2,238

     

     

     

    11,861

     

    Additions to property, plant, and equipment

     

     

    (1,962

    )

     

     

    —

     

    Issuance of long-term debt, net of issuance costs

     

     

    —

     

     

     

    2,975

     

    Repayment of debt

     

     

    (1,500

    )

     

     

    (2,288

    )

    Proceeds from sales of common stock through employee equity incentive plans

     

     

    491

     

     

     

    631

     

    Payment of dividends to stockholders

     

     

    —

     

     

     

    (1,063

    )

    Other financing

     

     

    (678

    )

     

     

    (444

    )

    Net cash provided by (used for) financing activities

     

     

    586

     

     

     

    14,867

     

    Net increase (decrease) in cash and cash equivalents

     

     

    1,444

     

     

     

    4,208

     

    Cash and cash equivalents, end of period1

     

    $

    9,693

     

     

    $

    11,287

     

    1

    Includes $50 million of cash recorded within other current assets on the Consolidated Condensed Balance Sheets relating to Altera cash held for sale.

    Intel Corporation

    Supplemental Operating Segment Results
     

     

     

    Three Months Ended

    (In Millions; Unaudited)

     

    Jun 28, 2025

     

     

    Intel Products

     

     

     

     

     

     

     

     

     

     

     

     

    CCG

     

    DCAI

     

    Total Intel Products

     

    Intel Foundry

     

    All Other1

     

    Corporate Unallocated

     

    Intersegment Eliminations

     

    Total Consolidated

    Revenue

     

    $

    7,871

     

    $

    3,939

     

    $

    11,810

     

    $

    4,417

     

     

    $

    1,053

     

    $

    —

     

     

    $

    (4,421

    )

     

    $

    12,859

     

    Cost of sales and operating expenses

     

     

    5,818

     

     

    3,306

     

     

    9,124

     

     

    7,585

     

     

     

    984

     

     

    2,755

     

     

     

    (4,413

    )

     

     

    16,035

     

    Operating income (loss)

     

    $

    2,053

     

    $

    633

     

    $

    2,686

     

    $

    (3,168

    )

     

    $

    69

     

    $

    (2,755

    )

     

    $

    (8

    )

     

    $

    (3,176

    )

     

     

    Three Months Ended

    (In Millions; Unaudited)

     

    Jun 29, 2024

     

     

    Intel Products

     

     

     

     

     

     

     

     

     

     

     

     

    CCG

     

    DCAI

     

    Total Intel Products

     

    Intel Foundry

     

    All Other1

     

    Corporate Unallocated

     

    Intersegment Eliminations

     

    Total Consolidated

    Revenue

     

    $ 8,143

     

    $ 3,805

     

    $ 11,948

     

    $ 4,282

     

    $ 881

     

    $ —

     

    $ (4,278)

     

    $ 12,833

    Cost of sales and operating expenses

     

    5,502

     

    3,563

     

    9,065

     

    7,084

     

    927

     

    1,708

     

    (3,987)

     

    14,797

    Operating income (loss)

     

    $ 2,641

     

    $ 242

     

    $ 2,883

     

    $ (2,802)

     

    $ (46)

     

    $ (1,708)

     

    $ (291)

     

    $ (1,964)

    1

    The “All Other” category includes the results of operations from other non-reportable segments, including our Altera and Mobileye businesses, our IMS business, startup businesses that support our initiatives, and historical results of operations from divested businesses.

    For information about our operating segments, including the nature of segment revenues and expenses, and a reconciliation of our operating segment revenue and operating income (loss) to our consolidated results, refer to our Q2 2025 Form 10-Q.

    Intel Corporation

    Explanation of Non-GAAP Measures

    In addition to disclosing financial results in accordance with US GAAP, this document references non-GAAP financial measures below. We believe these non-GAAP financial measures provide investors with useful supplemental information about our operating performance, enable comparison of financial trends and results between periods where certain items may vary independent of business performance, and allow for greater transparency with respect to key metrics used by management in operating our business and measuring our performance. These non-GAAP financial measures are used in our performance-based RSUs and our cash bonus plans.

    Our non-GAAP financial measures reflect adjustments based on one or more of the following items, as well as the related effects to income taxes and net income (loss) attributable to non-controlling interests effects. Income tax effects are calculated using a fixed long-term projected tax rate. For 2025 and 2024, we determined the projected non-GAAP tax rate to be 12% and 13%, respectively. We project this long-term non-GAAP tax rate on at least an annual basis using a five-year non-GAAP financial projection that excludes the income tax effects of each adjustment. The projected non-GAAP tax rate also considers factors such as our tax structure, our tax positions in various jurisdictions, and key legislation in significant jurisdictions where we operate. This long-term non-GAAP tax rate may be subject to change for a variety of reasons, including the rapidly evolving global tax environment, significant changes in our geographic earnings mix, or changes to our strategy or business operations. Management uses this non-GAAP tax rate in managing internal short- and long-term operating plans and in evaluating our performance; we believe this approach facilitates comparison of our operating results and provides useful evaluation of our current operating performance. Non-GAAP adjustments attributable to non-controlling interests are calculated by adjusting for the minority stockholder portion of non-GAAP adjustments we make for relevant acquisition-related costs, share-based compensation, restructuring and other charges, and income tax effects, as applicable to each majority-owned subsidiary.

    Our non-GAAP financial measures should not be considered a substitute for, or superior to, financial measures calculated in accordance with US GAAP, and the financial results calculated in accordance with US GAAP and reconciliations from these results should be carefully evaluated.

    Non-GAAP adjustment or measure

    Definition

    Usefulness to management and investors

    Acquisition-related adjustments

    Amortization of acquisition-related intangible assets consists of amortization of intangible assets such as developed technology, brands, and customer relationships acquired in connection with business combinations. Charges related to the amortization of these intangibles are recorded within both cost of sales and MG&A in our US GAAP financial statements. Amortization charges are recorded over the estimated useful life of the related acquired intangible asset, and thus are generally recorded over multiple years.

    We exclude amortization charges for our acquisition-related intangible assets for purposes of calculating certain non-GAAP measures because these charges are inconsistent in size and are significantly impacted by the timing and valuation of our acquisitions. These adjustments facilitate a useful evaluation of our current operating performance and comparison to our past operating performance and provide investors with additional means to evaluate cost and expense trends.

    Share-based compensation

    Share-based compensation consists of charges related to our employee equity incentive plans.

    We exclude charges related to share-based compensation for purposes of calculating certain non-GAAP measures because we believe these adjustments provide comparability to peer company results and because these charges are not viewed by management as part of our core operating performance. We believe these adjustments provide investors with a useful view, through the eyes of management, of our core business model, how management currently evaluates core operational performance, and additional means to evaluate expense trends, including in comparison to other peer companies.

    Restructuring and other charges

    Restructuring charges are costs associated with restructuring plans and are primarily related to employee severance and benefit arrangements. Q2 2025 primarily includes charges associated with the 2025 Restructuring Plan. Other charges include periodic goodwill and asset impairments, and other costs associated with certain non-core activities. Q2 2024 includes a charge arising out of the R2 litigation.

    We exclude restructuring and other charges, including any adjustments to charges recorded in prior periods, for purposes of calculating certain non-GAAP measures because these costs do not reflect our core operating performance. These adjustments facilitate a useful evaluation of our core operating performance and comparisons to past operating results and provide investors with additional means to evaluate expense trends.

    (Gains) losses on equity investments, net

    (Gains) losses on equity investments, net consists of ongoing mark-to-market adjustments on marketable equity securities, observable price adjustments on non-marketable equity securities, related impairment charges, and the gains (losses) from the sale of equity investments and other.

    We exclude these non-operating gains and losses for purposes of calculating certain non-GAAP measures to provide comparability between periods. The exclusion reflects how management evaluates the core operations of the business.

    (Gains) losses from divestiture

    (Gains) losses are recognized at the close of a divestiture, or over a specified deferral period when deferred consideration is received at the time of closing.

    We exclude gains or losses resulting from divestitures for purposes of calculating certain non-GAAP measures because they do not reflect our current operating performance. These adjustments facilitate a useful evaluation of our current operating performance and comparisons to past operating results.

    Adjusted free cash flow

    We reference a non-GAAP financial measure of adjusted free cash flow, which is used by management when assessing our sources of liquidity, capital resources, and quality of earnings. Adjusted free cash flow is operating cash flow adjusted for (1) additions to property, plant, and equipment, net of proceeds from capital-related government incentives and net partner contributions, and (2) payments on finance leases.

    This non-GAAP financial measure is helpful in understanding our capital requirements and sources of liquidity by providing an additional means to evaluate the cash flow trends of our business.

    Net capital spending

    We reference a non-GAAP financial measure of net capital spending, which is additions to property, plant, and equipment, net of proceeds from capital-related government incentives and net partner contributions.

    We believe this measure provides investors with useful supplemental information about our capital investment activities and capital offsets, and allows for greater transparency with respect to a key metric used by management in operating our business and measuring our performance.

    Intel Corporation

    Supplemental Reconciliations of GAAP Actuals to Non-GAAP Actuals

    Set forth below are reconciliations of the non-GAAP financial measure to the most directly comparable US GAAP financial measure. These non-GAAP financial measures should not be considered a substitute for, or superior to, financial measures calculated in accordance with US GAAP, and the reconciliations from US GAAP to Non-GAAP actuals should be carefully evaluated. Please refer to “Explanation of Non-GAAP Measures” in this document for a detailed explanation of the adjustments made to the comparable US GAAP measures, the ways management uses the non-GAAP measures, and the reasons why management believes the non-GAAP measures provide useful information for investors.

     

     

    Three Months Ended

    (In Millions, Except Per Share Amounts; Unaudited)

     

    Jun 28, 2025

     

    Jun 29, 2024

    GAAP gross profit

     

    $

    3,542

     

     

    $

    4,547

     

    Acquisition-related adjustments

     

     

    101

     

     

     

    224

     

    Share-based compensation

     

     

    170

     

     

     

    195

     

    Non-GAAP gross profit

     

    $

    3,813

     

     

    $

    4,966

     

    GAAP gross margin percentage

     

     

    27.5

    %

     

     

    35.4

    %

    Acquisition-related adjustments

     

     

    0.8

    %

     

     

    1.7

    %

    Share-based compensation

     

     

    1.3

    %

     

     

    1.5

    %

    Non-GAAP gross margin percentage

     

     

    29.7

    %

     

     

    38.7

    %

    GAAP R&D and MG&A

     

    $

    4,828

     

     

    $

    5,568

     

    Acquisition-related adjustments

     

     

    (18

    )

     

     

    (41

    )

    Share-based compensation

     

     

    (494

    )

     

     

    (585

    )

    Non-GAAP R&D and MG&A

     

    $

    4,316

     

     

    $

    4,942

     

    GAAP operating income (loss)

     

    $

    (3,176

    )

     

    $

    (1,964

    )

    Acquisition-related adjustments

     

     

    119

     

     

     

    265

     

    Share-based compensation

     

     

    664

     

     

     

    780

     

    Restructuring and other charges

     

     

    1,890

     

     

     

    943

     

    Non-GAAP operating income (loss)

     

    $

    (503

    )

     

    $

    24

     

    GAAP operating margin (loss)

     

     

    (24.7

    )%

     

     

    (15.3

    )%

    Acquisition-related adjustments

     

     

    0.9

    %

     

     

    2.1

    %

    Share-based compensation

     

     

    5.2

    %

     

     

    6.1

    %

    Restructuring and other charges

     

     

    14.7

    %

     

     

    7.3

    %

    Non-GAAP operating margin (loss)

     

     

    (3.9

    )%

     

     

    0.2

    %

    GAAP tax rate

     

     

    (9.2

    )%

     

     

    17.5

    %

    Income tax effects

     

     

    21.2

    %

     

     

    (4.5

    )%

    Non-GAAP tax rate

     

     

    12.0

    %

     

     

    13.0

    %

    GAAP net income (loss) attributable to Intel

     

    $

    (2,918

    )

     

    $

    (1,610

    )

    Acquisition-related adjustments

     

     

    119

     

     

     

    265

     

    Share-based compensation

     

     

    664

     

     

     

    780

     

    Restructuring and other charges

     

     

    1,890

     

     

     

    943

     

    (Gains) losses on equity investments, net

     

     

    (502

    )

     

     

    120

     

    (Gains) losses from divestiture

     

     

    —

     

     

     

    (39

    )

    Adjustments attributable to non-controlling interest

     

     

    (21

    )

     

     

    (18

    )

    Income tax effects

     

     

    327

     

     

     

    (358

    )

    Non-GAAP net income (loss) attributable to Intel

     

    $

    (441

    )

     

    $

    83

     

    (In Millions, Except Per Share Amounts; Unaudited)

     

    Jun 28, 2025

     

    Jun 29, 2024

    GAAP earnings (loss) per share attributable to Intel—diluted

     

    $

    (0.67

    )

     

    $

    (0.38

    )

    Acquisition-related adjustments

     

     

    0.03

     

     

     

    0.06

     

    Share-based compensation

     

     

    0.15

     

     

     

    0.18

     

    Restructuring and other charges

     

     

    0.43

     

     

     

    0.22

     

    (Gains) losses on equity investments, net

     

     

    (0.11

    )

     

     

    0.03

     

    (Gains) losses from divestiture

     

     

    —

     

     

     

    (0.01

    )

    Adjustments attributable to non-controlling interest

     

     

    —

     

     

     

    —

     

    Income tax effects

     

     

    0.07

     

     

     

    (0.08

    )

    Non-GAAP earnings (loss) per share attributable to Intel—diluted

     

    $

    (0.10

    )

     

    $

    0.02

     

     

     

     

     

     

    GAAP net cash provided by (used for) operating activities

     

    $

    2,050

     

     

    $

    2,292

     

    Additions to property, plant, and equipment (gross capital expenditures)

     

     

    (4,492

    )

     

     

    (5,682

    )

    Proceeds from capital-related government incentives

     

     

    145

     

     

     

    107

     

    Partner contributions, net

     

     

    1,250

     

     

     

    11,438

     

    Net purchase of property, plant, and equipment (net capital expenditures)

     

     

    (3,097

    )

     

     

    5,863

     

    Payments on finance leases

     

     

    (3

    )

     

     

    —

     

    Adjusted free cash flow

     

    $

    (1,050

    )

     

    $

    8,155

     

    GAAP net cash provided by (used for) investing activities

     

    $

    (2,086

    )

     

    $

    (9,165

    )

    GAAP net cash provided by (used for) financing activities

     

    $

    782

     

     

    $

    11,237

     

    Intel Corporation

    Supplemental Reconciliations of GAAP Outlook to Non-GAAP Outlook

    Set forth below are reconciliations of the non-GAAP financial measure to the most directly comparable US GAAP financial measure. These non-GAAP financial measures should not be considered a substitute for, or superior to, financial measures calculated in accordance with US GAAP, and the financial outlook prepared in accordance with US GAAP and the reconciliations from this Business Outlook should be carefully evaluated. Please refer to “Explanation of Non-GAAP Measures” in this document for a detailed explanation of the adjustments made to the comparable US GAAP measures, the ways management uses the non-GAAP measures, and the reasons why management believes the non-GAAP measures provide useful information for investors.

    (Unaudited)

     

    Q3 2025 Outlook1

     

     

    Approximately

    GAAP gross margin percentage

     

     

    34.1

    %

    Acquisition-related adjustments

     

     

    0.8

    %

    Share-based compensation

     

     

    1.1

    %

    Non-GAAP gross margin percentage

     

     

    36.0

    %

     

     

     

    GAAP tax rate

     

     

    (23

    )%

    Income tax effects

     

     

    35

    %

    Non-GAAP tax rate

     

     

    12

    %

     

     

     

    GAAP earnings (loss) per share attributable to Intel—diluted

     

    $

    (0.24

    )

    Acquisition-related adjustments

     

     

    0.02

     

    Share-based compensation

     

     

    0.14

     

    Restructuring and other charges

     

     

    0.07

     

    Adjustments attributable to non-controlling interest

     

     

    (0.01

    )

    Income tax effects

     

     

    0.02

     

    Non-GAAP earnings (loss) per share attributable to Intel—diluted

     

    $

    0.00

     

    1

    Non-GAAP gross margin percentage and non-GAAP earnings (loss) per share attributable to Intel outlook based on the mid-point of the revenue range.

    Intel Corporation

    Supplemental Reconciliations of Other GAAP to Non-GAAP Forward-Looking Estimates

    Set forth below are reconciliations of the non-GAAP financial measure to the most directly comparable US GAAP financial measure. These non-GAAP financial measures should not be considered a substitute for, or superior to, financial measures calculated in accordance with US GAAP, and the reconciliations should be carefully evaluated. Please refer to “Explanation of Non-GAAP Measures” in this document for a detailed explanation of the adjustments made to the comparable US GAAP measures, the ways management uses the non-GAAP measures, and the reasons why management believes the non-GAAP measures provide useful information for investors.

    (In Billions; Unaudited)

     

     

    Full-Year 2025

     

    Full-Year 2026

     

     

     

    Approximately

     

    Approximately

     

     

     

     

     

     

    GAAP additions to property, plant and equipment (gross capital expenditures)

     

     

    $

    18.0

     

     

     

    Proceeds from capital-related government incentives

     

     

    (3.0 – 5.0)

     

     

    Partner contributions, net

     

     

    (4.0 – 5.0)

     

     

    Non-GAAP net capital expenditures

     

     

    $8.0 – $11.0

     

     

     

     

     

     

     

     

    GAAP operating expenses

     

     

    $

    22.1

     

     

    $

    19.0

     

    Acquisition-related adjustments

     

     

     

    (0.1

    )

     

     

    (0.1

    )

    Share-based compensation

     

     

     

    (2.5

    )

     

     

    (2.9

    )

    Restructuring and other charges

     

     

     

    (2.5

    )

     

     

    —

     

    Non-GAAP operating expenses

     

     

    $

    17.0

     

     

    $

    16.0

     

     

    Investor Relations

    investor.relations@intel.com

    Sophie Metzger

    Media Relations

    sophie.metzger@intel.com

    Source: Intel Corporation

    Released Jul 24, 2025 • 4:01 PM EDT

    Continue Reading

  • Pacific music legend George “Fiji” Veikoso dies aged 55

    Pacific music legend George “Fiji” Veikoso dies aged 55

    On the program today

    Fijian-born recording artist and Pacific music legend George “Fiji” Veikoso has died at the age of 55 in Suva.

    an opposition MP in Solomon Islands says the country risks creating a wedge in the solidarity of the Pacific Islands Forum if it refuses to allow Taiwan to attend.

    Pacific leaders celebrate after the International Court of Justice ruled that states that fail to deal with climate change could be subject to reparations.

    Polling in Papua New Guinea’s Porgera-Paiela district has been completed peacefully, despite the hijacking of ballot boxes and the destruction of key bridges.

    In Fiji, the National Geographic Pristine Seas expedition sets sail to study the health of Fiji’s oceans.

    And the Solomon Islands women’s captain opens up on the side’s historic win at the OFC Nations Cup.

    Continue Reading

  • BISE Faisalabad matric results 2025: Here’s how to check online – ARY News

    1. BISE Faisalabad matric results 2025: Here’s how to check online  ARY News
    2. Student from Lawrence College tops Pindi board’s SSC exams  Dawn
    3. BISE reveals matric position holders  The Express Tribune
    4. Secondary School Annual Exams: Lahore Board announces results  Business Recorder
    5. BISE Multan Class 10th Result 2025 Officially Announced  TechJuice

    Continue Reading

  • First Came Ozempic Face. Now People Are Dealing With Ozempic Hair and Muscle Loss

    First Came Ozempic Face. Now People Are Dealing With Ozempic Hair and Muscle Loss

    Ever since Ozempic flooded the mainstream consciousness, the controversial weight loss drug of choice has come with some well-documented downsides. Many have dealt with the infamous Ozempic face, which experts describe as rapid weight loss to the face and loss of elasticity in the skin, causing one to look much older. “Ozempic face can look gaunt, deflated, and saggy,” New York-based facial plastic surgeon Dr. Jennifer Levine once told Vogue. “Think raisin as opposed to grape!”

    Now, people are noticing that Ozempic and similar GLP-1 drugs (Mounjaro, Wegovy, Rybelsus, and Zepound, to name a few) are affecting their hairline and possibly weakening their muscle strength. So what gives?

    Why is this happening?

    Though some studies link these drugs to hair loss, experts still say it is not a direct side effect of GLP-1s like Ozempic or other medications like Mounjaro. Marisa Garshick, MD, board-certified dermatologist at MDCS Dermatology, explains that it’s actually more of an indirect result of rapid weight loss, nutritional deficiencies, or stress on the body. “Telogen effluvium is a type of hair shedding that may be noticed a few months after the body experiences some type of change or stress,” says Dr. Garshick (it’s akin to the dramatic hair shedding some saw in the months post-COVID-19). “People on GLP-1s may not actually notice hair shedding or thinning for several months after they are on it.”

    As for muscle loss—that’s just a general side effect of losing weight, regardless of whether the impetus is diet, exercise, surgery, or a medication like Ozempic. Holly Lofton, MD, director of the medical weight management program at NYU Langone Health, tells Vogue that experts see medications like Wegovy and Zepbound are causing the same—and sometimes more—amount of muscle loss as one might experience through more traditional weight loss methods. Studies show that 25 to 30% of the total weight loss caused by calorie restriction and exercise comes from lean body mass, which includes muscles. So if someone were to lose 20 pounds, she says around 5 to 6 pounds of that might be muscle that is lost. Studies on medications like Wegovy and Zepbound show patients can lose roughly 15 to 22% of their total weight, with about 25% of that weight loss being lean muscle mass. “These drugs are not necessarily muscle-sparing,” she says. “However, because people tend to lose more total weight on these medications, the absolute amount of muscle loss can be greater (unless we intervene with resistance training and adequate protein intake).”

    What can you do about it?

    There are a few things you can do to treat hair and muscle loss that you might experience when on these medications. Dr. Garshick says that it is normal to shed about 50 to 100 hairs a day, so you should only be concerned if you notice significantly more hair falling out or if your hair loss persists longer than three to six months. If that is the case, she recommends seeing a board-certified dermatologist to be properly evaluated. “Since telogen effluvium is considered a temporary process, once the weight stabilizes, it is possible the hair loss will slow down and hair regrowth will resume and normalize even without doing any specific intervention,” she says. “While this process can take six to 12 months, providing reassurance that it can get better on its own is often sufficient.”

    She says getting bloodwork done to see if there are hormonal changes or nutritional deficiencies that can be addressed through diet (making sure you are consuming enough protein is key) or the use of oral supplements like Nutrafol or Wellbell. You can also turn to thickening and volumizing shampoos, like the Nioxin Hair Fall Defense Shampoo or the Vegamour GRO Revitalizing Shampoo, and leave-in products like the Virtue Flourish Density Booster, to help increase hair density. For more intense treatments, you can inquire about platelet-rich plasma (PRP) therapy to stimulate hair growth.


    Continue Reading

  • ‘Phenomenal’: Zak Crawley hails Ben Stokes’ resurgence after five-wicket haul | England v India 2025

    ‘Phenomenal’: Zak Crawley hails Ben Stokes’ resurgence after five-wicket haul | England v India 2025

    Zak Crawley hailed Ben Stokes’s “phenomenal” resurgence with the ball as the England captain took his first Test five-wicket haul in eight years, driving the hosts into control of the fourth Test in Manchester.

    Stokes finished with figures of five for 72 before Crawley struck 84 as England closed the second day on 225 for two, trailing India’s first-innings total by 133 runs. The former has recovered from a hamstring tear, sustained against New Zealand late last year, to become his side’s leading bowler this summer. He sits at the top of the series’ wicket-taking charts with 16 at an average of 24.75.

    Asked if he saw similarities with Stokes now and the bowler from a few years ago, when South Africa were ripped apart at Newlands in 2020 with three late match-winning wickets, Crawley replied: “There are so many similarities to that pace-wise.”.

    “He was bowling quickly back then and he’s got that pace back now. And the way he gets that away movement from the right-handers, that zip, which is as much as anyone in the world. He gets that bounce and he’s a proper wicket-taker, and he can make things happen. That was certainly the case when I first came into the side back then, and he seems to have got that back now, which is a phenomenal effort considering the injuries he’s had. And, well, he’s a little bit older now, so a phenomenal effort.”

    Crawley’s opening stand of 166 with Ben Duckett on Thursday came after the pair had been involved in a tetchy exchange with the Indian fielders on the third evening at Lord’s, taking their time as Crawley faced one over before the close. India’s captain, Shubman Gill, questioned whether England’s behaviour had been “in the spirit of the game”.

    “I sit in my spot until the umpires go out, and I saw the umpires go out and I walked out. I wasn’t aware that we were 90 seconds late, but fair enough,” said Crawley.

    skip past newsletter promotion

    “I’ve always enjoyed that part of cricket, to be honest, especially when you’re batting, and it’s two of you against 11 and they’re desperate to get you out and they’re chirping you. Most of the time I’d probably let it slide and then other times I feel like it’s a good chance to put it back on them. And Lord’s was, you know – I loved that little eight-minute passage. No one stepped over the line. I thought everyone was in good spirits. It was just competitive cricket.”

    Continue Reading

  • Pentagon not impacted by Microsoft Sharepoint hack, tech chief says – Nextgov/FCW

    1. Pentagon not impacted by Microsoft Sharepoint hack, tech chief says  Nextgov/FCW
    2. Disrupting active exploitation of on-premises SharePoint vulnerabilities  Microsoft
    3. Microsoft says some SharePoint server hackers now using ransomware  Dawn
    4. Nuclear Weapons Agency Breached in Microsoft SharePoint Hack  Bloomberg
    5. DHS impacted in hack of Microsoft SharePoint products, people familiar say  Nextgov/FCW

    Continue Reading

  • Dead Island 2′ arrives for Mac users on Apple Silicon

    Dead Island 2′ arrives for Mac users on Apple Silicon

    “Dead Island 2” is now available for Mac users through the Mac App Store, expanding the zombie action RPG to a new platform.

    The game first launched on April 21, 2023, for PlayStation, Xbox, and Windows PC via the Epic Games Store. It later arrived on Steam on April 22, 2024.

    The new Mac version, released on July 24, 2025, is part of Apple’s growing effort to bring AAA titles to macOS, including full support for Apple Silicon.

    Dead Island 2 on Mac is listed as the “Ultimate Edition” and is available as a universal app through the Mac App Store. It supports MetalFX upscaling and takes advantage of hardware acceleration on M1, M2, and M3 chips.

    As with other major Mac game releases, there’s no need for a third-party launcher or streaming service.

    The game includes the base campaign, expansion packs, and additional content in one package. However, cross-play with Windows or console users is not currently supported.

    Device requirements

    Dead Island 2 is only available on Macs with Apple Silicon chips. It requires macOS 13.0 or later and is optimized for M1, M2, and M3 systems.

    The game includes the base campaign, expansion packs, and additional content in one package.

    The game joins other recent high-profile Mac releases such as Resident Evil Village, No Man’s Sky, and Death Stranding. Apple has promoted these titles at recent WWDC events as part of a broader strategy to legitimize macOS as a viable gaming platform.

    Developers are increasingly porting games to Mac using Apple’s Game Porting Toolkit, along with new tools in Xcode and Metal 3. These efforts align with the company’s long-term push to unify performance across iPhone, iPad, and Mac using Apple Silicon.

    Dead Island 2 is available now on the Mac App Store for $69.99. It’s also available on Steam, Epic Games Store, PlayStation, and Xbox.

    Continue Reading

  • Quantum Brilliance and Collaborators Outline Path for Scalable Diamond Quantum Technology via Bottom-Up Fabrication

    Quantum Brilliance and Collaborators Outline Path for Scalable Diamond Quantum Technology via Bottom-Up Fabrication

    Quantum Brilliance, an Australian diamond quantum startup, in conjunction with RMIT University, La Trobe University, and Fraunhofer IAF, has published a paper titled “Bottom-up fabrication of scalable room-temperature diamond quantum computing and sensing technologies.” Appearing in the journal Mater. Quantum Technol., this paper outlines a method for creating and scaling diamond quantum technology by addressing the challenge of precisely fabricating qubits (Nitrogen-Vacancy (NV) centers) in diamond.

    The paper proposes the use of atomic scale fabrication (ASF), specifically a hydrogen depassivation lithography (HDL) technique, for the bottom-up fabrication of NV centers. This multi-step procedure is envisioned as a method for deterministic, sub-nanometre spatial precision and the preservation of crystal purity. It involves preparing the diamond substrate and surface, using Scanning Tunneling Microscopy (STM) for imaging and targeted hydrogen desorption to create active adsorption sites, exposing the surface to an N-containing precursor gas for selective chemisorption, and overgrowing using chemical vapor deposition (CVD) to incorporate N into the diamond lattice as NV centers.

    This proposed method is intended to enable the realization of integrated diamond quantum devices for room-temperature quantum computing and sensing. For quantum computing, it aims to facilitate arrays of closely-spaced NV centers (e.g., 5–10 nm separation) for two-qubit gate operations. For quantum sensing, it seeks to enhance device sensitivities by enabling scalable production of homogeneous arrays of identical NV centers in a low-noise environment. The authors, including Marcus Doherty, Chief Scientific Officer at Quantum Brilliance, contend that while HDL-based fabrication of NV centers requires engineering, there are no fundamental impediments to its feasibility.

    The research identifies key challenges in its development, such as achieving higher spatial accuracy, optimizing N-based molecular adsorption chemistry, and improving N retention and N-to-NV conversion yields during overgrowth. This perspective encourages continued experimental and theoretical progress through sustained community effort and cross-discipline collaboration in the field of atom-scale NV fabrication.

    Read more about this research on the Quantum Brilliance newsdesk here and the paper in Mater. Quantum Technol. here.

    July 24, 2025

    Print Friendly, PDF & Email


    Continue Reading